Previous 10 | Next 10 |
2023-12-26 11:15:43 ET Summary Syndax Pharmaceuticals, Inc. has experienced a roller coaster ride in the stock market, but is currently up 80% from its lows in October. The company has two candidates in development that are poised to garner FDA approval in 2024 and also just fille...
2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...
2023-12-18 09:00:00 ET Summary Incyte stock has experienced significant volatility and decline throughout the year. INCY is focused on updating its revenue base but lacks any strong near term catalysts. Incyte has a pending LOE issue. This is my second Incyte (INCY) ...
2023-12-15 14:30:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company’s making these strides have incredible results to show...
2023-12-14 14:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-12 16:54:38 ET More on Incyte Incyte Corporation (INCY) Q3 2023 Earnings Call Transcript Incyte Corporation 2023 Q3 - Results - Earnings Call Presentation Incyte: One Of The Most Undervalued Pharmaceuticals Goldman Sachs cuts Incyte to hold, cites Jak...
- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment - Data are featured in the Plenary Scientific Session at the 65 th American Society of Hematology Ann...
2023-12-08 15:00:12 ET More on the markets S&P 500: New All-Time Highs Before A Major Sell-Off S&P 500 Forecast 2024: Muddling Through Only Thing That Matters Is Price; Nasdaq Has Further To Go - Cestrian Capital Research Money market funds attract mo...
2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...
2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...